First malaria vaccine hits 1 million dose milestone : Goats and Soda The vaccine couldn't have come at a more critical time, with a surge in cases and deaths from malaria during the pandemic. But its efficacy — and its schedule — are far from ideal.

First malaria vaccine hits 1 million dose milestone — although it has its shortcomings

  • Download
  • <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript


More than 1 million African children have now received doses of the world's first vaccine against malaria. Now, the timing is critical. During the pandemic, the mosquito-borne disease saw a surge in cases and deaths. But there are concerns about just how effective the vaccine will be. Here's NPR's Ari Daniel.

ARI DANIEL, BYLINE: Dr. Kwaku Poku Asante of Ghana was a few minutes late to our interview because he'd just gotten a phone call.

KWAKU POKU ASANTE: I've just been called that my son, who's in high school, has a fever. I'm not sure whether it's malaria, but I'm troubled.

DANIEL: Asante's son is 14, so not in the high-risk group of 5 and under. Still, parents in much of Africa are terrified by a fever, which may signal malaria. The disease defines much of Asante's professional life, too, as director of the Kintampo Health Research Centre.

ASANTE: I've witnessed many, many children at the hospital, sometimes come in convulsing. Sometimes they come in with severe anemia.

DANIEL: And of course, sometimes these children die. In 2020, the World Health Organization counted almost a quarter billion cases of malaria in kids and adults, resulting in 627,000 deaths. For years, the best protective measures have been preventative - insecticide-treated bed nets, anti-malarial pills, reducing mosquito habitat. Dr. Rose Jalang'o is with Kenya's Ministry of Health and says despite these interventions, progress against the disease had plateaued.

ROSE JALANG'O: At that point, we needed new tools to further reduce the burden of malaria disease.

DANIEL: Just such a new tool arrived last fall when the WHO authorized a malaria vaccine, the first-ever against a parasitic disease to be rolled out in Ghana, Malawi and Kenya. Now, over a million kids have received doses.

JALANG'O: Wow. This is a total game-changer. Having a malaria vaccine has the potential of reducing the deaths associated with malaria.

DANIEL: Jalang'o coordinates Kenya's malaria vaccination program.

JALANG'O: The community members are reporting their children - they are having less frequent attacks of malaria.

DANIEL: The data are somewhat less heartening. The vaccine only reduces severe malaria by 30%, and there's a wide margin of error on that figure. It requires three or four doses by age 2, a schedule that can be challenging for families. And even though children gain a measure of protection at a vulnerable age, efficacy can wane.

DYANN WIRTH: You know, it's not perfect. Would I like a vaccine that's 100% effective and easily given in one dose? Absolutely. But that's not the reality.

DANIEL: Dyann Wirth is a geneticist at the Harvard T.H. Chan School of Public Health and chairs an independent malaria advisory group at the WHO.

WIRTH: The vaccine shows some protection. I think not using it would not be justifiable. It is important that it be available to the populations that can benefit.

DANIEL: Health professionals on the ground say this vaccine isn't intended to replace other measures like bed nets. It's one more layer of protection. Kwaku Poku Asante again.

ASANTE: It's taken us about 30 to 40 years to get here.

DANIEL: And now, other vaccines and preventative treatments are in the works.

ASANTE: And therefore, at this point, if there is a vaccine, we can only improve on it over time.

DANIEL: Ari Daniel, NPR News.

Copyright © 2022 NPR. All rights reserved. Visit our website terms of use and permissions pages at for further information.

NPR transcripts are created on a rush deadline by an NPR contractor. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.